Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 245-826-4 | CAS number: 23694-14-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
Levosulpiride does not cause any adverse effect to reproduction. Other studies suggest that sulpiride can alter reproductive function in female offspring rats and may impact the reproductive development of male rats: the testes seem to be the main target organ at adulthood.
Link to relevant study records
- Endpoint:
- fertility, other
- Remarks:
- reproductive development of female offspring
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- abstract
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- The aim of the study was to investigate whether maternal exposure to Sulpiride during lactation could impair reproductive development of female offspring.
- GLP compliance:
- not specified
- Limit test:
- no
- Specific details on test material used for the study:
- Sulpiride and sulpiride HCl are expected to be similar for this endpoint.
- Species:
- rat
- Strain:
- not specified
- Sex:
- female
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Duration of treatment / exposure:
- The dams were treated throughout the lactation period.
- Frequency of treatment:
- Daily.
- Dose / conc.:
- 2.5 mg/kg bw/day (nominal)
- Remarks:
- SUL 2.5mg group
- Dose / conc.:
- 25 mg/kg bw/day (nominal)
- Remarks:
- SUL 25mg group
- Control animals:
- yes, concurrent vehicle
- Litter observations:
- During early life, body weight, anogenital distance, and vaginal opening were analyzed on the female offspring. In adulthood, estrous cycle, sexual behavior, estrogen levels as well as the weight of the reproductive organs were evaluated.
- Details on results:
- There were no differences regarding body weight, anogenital distance, puberty onset, frequency and duration of the estrous cycle and estradiol levels on female offspring. Nonetheless, there were changes in sexual behavior. There was an increase in the number of observations in reflex magnitude 0 (absence of lordosis) and reflex magnitude 2 as well as a reduction of reflex magnitude 3 in the rats of SUL 25mg group in relation to the Control group, suggesting a decrease in sexual receptivity of these animals.
- Conclusions:
- Study results suggest that maternal exposure to Sulpiride can alter reproductive function in female offspring rats.
- Executive summary:
The dams were treated daily by gavage with Sulpiride doses of 2.5mg/Kg (SUL 2.5mg group) and 25mg/Kg (SUL 25mg group), or distilled water (Control group) throughout the lactation period. During early life, body weight, anogenital distance, and vaginal opening were analyzed on the female offspring. In adulthood, estrous cycle, sexual behavior, estrogen levels as well as the weight of the reproductive organs were evaluated. There were no differences regarding body weight, anogenital distance, puberty onset, frequency and duration of the estrous cycle and estradiol levels on female offspring. Nonetheless, there were changes in sexual behavior. There was an increase in the number of observations in reflex magnitude 0 (absence of lordosis) and reflex magnitude 2 as well as a reduction of reflex magnitude 3 in the rats of SUL 25mg group in relation to the Control group, suggesting a decrease in sexual receptivity of these animals. These results demonstrate that maternal exposure to Sulpiride can alter reproductive function in female offspring rats.
- Endpoint:
- fertility, other
- Remarks:
- male offspring reproductive development
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- abstract
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- The aim of the study was to evaluate if maternal exposure to sulpiride during lactation could disrupt maternal care and/or male offspring reproductive development.
- GLP compliance:
- not specified
- Limit test:
- no
- Specific details on test material used for the study:
- Sulpiride and sulpiride HCl are expected to be similar for this endpoint.
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Duration of treatment / exposure:
- The dams were treated during lactation.
- Frequency of treatment:
- Daily
- Dose / conc.:
- 2.5 mg/kg bw/day (nominal)
- Dose / conc.:
- 25 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 20 dams/dose level
- Control animals:
- yes, concurrent vehicle
- Parental animals: Observations and examinations:
- Maternal behavior was analyzed on lactational days 5 and 10.
- Litter observations:
- Reproductive and behavioral parameters were analyzed at different time points.
- Conclusions:
- Study results show that maternal exposure to sulpiride during lactation may impact the reproductive development of male rats and the testes seem to be the main target organ at adulthood.
- Executive summary:
The dams were treated daily (gavage) with Sulpiride (SUL) 2.5mg/kg or 25mg/kg during lactation. Maternal behavior was analyzed on lactational days 5 and 10. In offspring, reproductive and behavioral parameters were analyzed at different time points. SUL treatment did not impair maternal care, but caused testicular damage in male offspring. At postnatal day 90, a reduction in testis weight, volume of seminiferous tubule and histopathological alterations such as an increased percentage of abnormal seminiferous tubules were observed. Data shows that maternal exposure to SUL during lactation may impact the reproductive development of male rats and the testes seem to be the main target organ at adulthood.
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- secondary literature
- Guideline:
- other: not specified
- GLP compliance:
- not specified
- Conclusions:
- Study results show that levosulpiride does not cause any adverse effect to reproduction. An increase of milk production was observed following treatment.
- Executive summary:
The oral administration of levosulpiride in rats at 75, 150 or 300 mg/kg/day is without direct effect on fertility, reproduction or organogenesis; more specifically, the administration of levosulpiride before coupling and 13 days after coupling showed that fertility in rats was unchanged, neither time periods nor sequence of gestation modified, newborn vitality was unaffected, no apparent damage to suckling occurred, and either preimplant or post-implant loss remained unchanged. Moreover, in the second generation coming from the zero generation treated with levosulpiride the newborn vitality overlapped with controls. The oral administration of levosulpiride at 10-25 mg/kg/day in rats and 25-50 mg/kg/day in rabbits during organogenesis caused no statistically significant change in weight gain by pregnant animals, in the number of foetal implants, in the number of dead or undeveloped foetuses, and in the weight of foetal offspring from animals treated compared to controls. In addition, some malformations were observed in treated rats and rabbits as well as in controls. Therefore, there is no substantial difference between control groups and treated animals. Teratogenic process in the two tested animal species can be excluded. Levosulpiride administered at dose of 75, 150 or 300 mg/kg/day by oral route in the final period of gestation and during the 21 days of suckling in rats neither changes fertility or gestation indices, nor modify newborn vitality indices. However, all treated groups have suckling indices somewhat lower than controls. The finding does not mean that there is decreased milk production following treatment. On the contrary, there is an increase in production that leads to better nutrition when there are many young and appearance of breast disease (congestion, inflammation) or when the young are few. These findings may be explained by the fact that levosulpiride under the right endocrine conditions and particularly at the end of pregnancy, induces an increase in milk production.
Referenceopen allclose all
The oral administration of levosulpiride in rats at 75, 150 or 300 mg/kg/day is without direct effect on fertility, reproduction or organogenesis; more specifically, the administration of levosulpiride before coupling and 13 days after coupling showed that fertility in rats was unchanged, neither time periods nor sequence of gestation modified, newborn vitality was unaffected, no apparent damage to suckling occurred, and either preimplant or post-implant loss remained unchanged. Moreover, in the second generation coming from the zero generation treated with levosulpiride the newborn vitality overlapped with controls. The oral administration of levosulpiride at 10-25 mg/kg/day in rats and 25-50 mg/kg/day in rabbits during organogenesis caused no statistically significant change in weight gain by pregnant animals, in the number of foetal implants, in the number of dead or undeveloped foetuses, and in the weight of foetal offspring from animals treated compared to controls. In addition, some malformations were observed in treated rats and rabbits as well as in controls. Therefore, there is no substantial difference between control groups and treated animals. Teratogenic process in the two tested animal species can be excluded. Levosulpiride administered at dose of 75, 150 or 300 mg/kg/day by oral route in the final period of gestation and during the 21 days of suckling in rats neither changes fertility or gestation indices, nor modify newborn vitality indices. However, all treated groups have suckling indices somewhat lower than controls. The finding does not mean that there is decreased milk production following treatment. On the contrary, there is an increase in production that leads to better nutrition when there are many young and appearance of breast disease (congestion, inflammation) or when the young are few. These findings may be explained by the fact that levosulpiride under the right endocrine conditions and particularly at the end of pregnancy, induces an increase in milk production.
Effect on fertility: via oral route
- Quality of whole database:
- The quality of database is limited as the reliability of the studies cannot be assigned.
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Effects on developmental toxicity
Description of key information
Levosulpiride does not cause any adverse effect to development.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- other information
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- secondary literature
- Guideline:
- other: not specified
- GLP compliance:
- not specified
- Species:
- rat
- Strain:
- not specified
- Conclusions:
- Study results show that levosulpiride does not cause any adverse effect to development.
- Executive summary:
The oral administration of levosulpiride in rats at 75, 150 or 300 mg/kg/day is without direct effect on fertility, reproduction or organogenesis; more specifically, the administration of levosulpiride before coupling and 13 days after coupling showed that fertility in rats was unchanged, neither time periods nor sequence of gestation modified, newborn vitality was unaffected, no apparent damage to suckling occurred, and either preimplant or post-implant loss remained unchanged. Moreover, in the second generation coming from the zero generation treated with levosulpiride the newborn vitality overlapped with controls. The oral administration of levosulpiride at 10-25 mg/kg/day in rats and 25-50 mg/kg/day in rabbits during organogenesis caused no statistically significant change in weight gain by pregnant animals, in the number of foetal implants, in the number of dead or undeveloped foetuses, and in the weight of foetal offspring from animals treated compared to controls. In addition, some malformations were observed in treated rats and rabbits as well as in controls. Therefore, there is no substantial difference between control groups and treated animals. Teratogenic process in the two tested animal species can be excluded. Levosulpiride administered at dose of 75, 150 or 300 mg/kg/day by oral route in the final period of gestation and during the 21 days of suckling in rats neither changes fertility or gestation indices, nor modify newborn vitality indices. However, all treated groups have suckling indices somewhat lower than controls. The finding does not mean that there is decreased milk production following treatment. On the contrary, there is an increase in production that leads to better nutrition when there are many young and appearance of breast disease (congestion, inflammation) or when the young are few. These findings may be explained by the fact that levosulpiride under the right endocrine conditions and particularly at the end of pregnancy, induces an increase in milk production.
Reference
The oral administration of levosulpiride in rats at 75, 150 or 300 mg/kg/day is without direct effect on fertility, reproduction or organogenesis; more specifically, the administration of levosulpiride before coupling and 13 days after coupling showed that fertility in rats was unchanged, neither time periods nor sequence of gestation modified, newborn vitality was unaffected, no apparent damage to suckling occurred, and either preimplant or post-implant loss remained unchanged. Moreover, in the second generation coming from the zero generation treated with levosulpiride the newborn vitality overlapped with controls. The oral administration of levosulpiride at 10-25 mg/kg/day in rats and 25-50 mg/kg/day in rabbits during organogenesis caused no statistically significant change in weight gain by pregnant animals, in the number of foetal implants, in the number of dead or undeveloped foetuses, and in the weight of foetal offspring from animals treated compared to controls. In addition, some malformations were observed in treated rats and rabbits as well as in controls. Therefore, there is no substantial difference between control groups and treated animals. Teratogenic process in the two tested animal species can be excluded. Levosulpiride administered at dose of 75, 150 or 300 mg/kg/day by oral route in the final period of gestation and during the 21 days of suckling in rats neither changes fertility or gestation indices, nor modify newborn vitality indices. However, all treated groups have suckling indices somewhat lower than controls. The finding does not mean that there is decreased milk production following treatment. On the contrary, there is an increase in production that leads to better nutrition when there are many young and appearance of breast disease (congestion, inflammation) or when the young are few. These findings may be explained by the fact that levosulpiride under the right endocrine conditions and particularly at the end of pregnancy, induces an increase in milk production.
Effect on developmental toxicity: via oral route
- Quality of whole database:
- The quality of database is limited as the reliability of the studies cannot be assigned.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Overall, data available are deemed to be inconclusive for classification.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.